论文部分内容阅读
为了探讨异基因造血干细胞移植(allo-HSCT)联合伊马替尼治疗Ph+急性淋巴细胞白血病(Philadelphiachromosome positive acute lymphoblastic leukemia,Ph+ALL)的疗效。对我院2007-2008年Ph+ALL患者3例所进行的allo-HSCT联合伊马替尼治疗效果进行了小结。3例Ph+ALL中1例接受同胞全相合移植,另2例为单倍体相合移植,移植前均处于完全缓解状态。3例患者在移植前后不同时间接受不同疗程的伊马替尼治疗,同时应用RT-PCR方法监测bcr/abl融合基因转录水平。随访日期至2009年10月21日。结果表明:3例患者均成功植入,未出现严重移植相关并发症;移植后bcr/abl融合基因处于低转录水平并逐渐转阴。结论:异基因造血干细胞移植联合伊马替尼是Ph+ALL有效的治疗方法。
To investigate the efficacy of allo-HSCT in combination with imatinib in the treatment of Ph + ALL patients with Ph + acute leukemia. The results of allo-HSCT combined with imatinib treatment in 3 patients with Ph + ALL in our hospital from 2007 to 2008 were summarized. One of the three Ph + ALL patients received sibling full complement transplantation and the other two were haploidentical allografts, all of which were in complete remission status before transplantation. Three patients received different courses of imatinib at different times before and after transplantation, and the transcription level of bcr / abl fusion gene was monitored by RT-PCR. Follow up date until October 21, 2009. The results showed that all the three patients were successfully implanted without any serious graft-related complications. The bcr / abl fusion gene was at a low transcription level and gradually turned negative after transplantation. Conclusion: Allogeneic hematopoietic stem cell transplantation combined with imatinib is an effective treatment for Ph + ALL.